Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPV23 Revaccination in 60–70-Year-Old Adults in Shanghai
ChiCTR2100041932Phase 4Recruiting
- Sponsor
- Shanghai Municipal Center for Disease Control and Prevention
- Start
- Jan 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease and bacterial pneumonia (2 arms), sponsored by Shanghai Municipal Center for Disease Control and Prevention. Primary endpoint: Antibody doubling rate. Started Jan 2021; status: recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal diseasebacterial pneumonia
Beyond the preview
Go deeper on ChiCTR2100041932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041932.